TriangleHEALTH PROFESSIONAL · SOURCE READING
Refractory Childhood AML (Induction Failure)
Source: Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 15, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent or Refractory Childhood AML
Induction failure (the morphological presence of 5% or greater marrow blasts at the end of all induction courses) is seen in 10% to 15% of children with AML. Subsequent outcomes for patients with induction failure are similar to those for patients with AML who relapse early (<12 months after remission).[4,23]
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice